In a groundbreaking development that could redefine therapeutic strategies in pediatric vascular anomalies, researchers have unraveled the molecular intricacies by which propranolol, a widely used beta-blocker, suppresses angiogenesis in infantile hemangiomas (IH). This discovery delineates a sophisticated regulatory axis involving the long non-coding RNA NEAT1, microRNA-194-5p, TRAF6, and the nuclear factor-kappa B (NF-κB) pathway, unearthing deeper insights into the drug’s efficacy and opening new avenues for targeted treatments.
Infantile hemangiomas represent the most common benign tumors in infants, typified by rapid endothelial proliferation and aberrant angiogenesis, which frequently resolves spontaneously but can cause significant morbidity in problematic locations. Despite propranolol’s established clinical use since its serendipitous discovery as an effective therapy for IH, the exact molecular mechanisms underpinning its anti-angiogenic behavior remained elusive until now. This study bridges that critical gap by unraveling the crosstalk between non-coding RNAs and inflammatory signaling cascades in endothelial cells.
Central to these findings is NEAT1, a nuclear paraspeckle assembly transcript whose role in endothelial biology has garnered considerable attention for its regulatory impact on gene expression and cellular physiology. Previous investigations had hinted at NEAT1’s involvement in angiogenesis, yet its precise function in IH context was unclear. Wang et al. demonstrated that propranolol treatment leads to a marked decrease in NEAT1 expression, suggesting a pivotal role for this lncRNA in modulating angiogenic signaling pathways.
Further probing revealed that NEAT1 acts as a competing endogenous RNA (ceRNA), sequestering miR-194-5p, a microRNA known to regulate gene transcripts involved in inflammatory and angiogenic responses. By downregulating NEAT1, propranolol indirectly elevates miR-194-5p levels, which in turn exerts repressive control over its target genes. This nuanced interaction delineates a sophisticated mechanism of post-transcriptional regulation impacting cellular proliferation and vascular remodeling.
One of the key target genes under miR-194-5p regulation is TRAF6 (TNF receptor associated factor 6), an adaptor molecule integral to the activation of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) signaling pathway. TRAF6 mediates downstream inflammatory responses that promote angiogenesis, thereby fostering the hypervascular environment characteristic of infantile hemangiomas. The repression of TRAF6 via miR-194-5p dampens NF-κB activity, effectively reversing the pathological angiogenic signaling.
The repression of NF-κB signaling by propranolol, mediated through this lncRNA and miRNA network, is particularly compelling because NF-κB has long been implicated in vascular inflammation, endothelial cell proliferation, and the regulation of proangiogenic factors such as VEGF. By targeting this axis, propranolol achieves not merely symptomatic control but interferes robustly with the molecular drivers of hemangioma growth.
Notably, these discoveries came from comprehensive experiments combining molecular biology techniques including RNA interference, quantitative PCR, and luciferase reporter assays, complemented by in vitro and in vivo analyses of endothelial cells derived from infantile hemangioma specimens. Such multi-dimensional approaches ensured rigorous validation of the NEAT1/miR-194-5p/TRAF6/NF-κB regulatory loop.
Moreover, the temporal dynamics of gene expression modulation upon propranolol administration offered insights into how early intervention might optimize therapeutic outcomes. The downregulation of NEAT1 and the subsequent cascade were detectable within hours of drug exposure, emphasizing the potential for rapid pharmacological impact on pathological angiogenesis.
These findings have profound implications beyond infantile hemangiomas. Given that pathological angiogenesis is a hallmark of numerous disorders including cancer, diabetic retinopathy, and rheumatoid arthritis, the described regulatory network may present as a universal target for broader anti-angiogenic therapies. The identification of NEAT1 as a critical modulator in this cascade expands the repertoire of non-coding RNAs considered druggable targets.
Furthermore, the study challenges conventional perceptions of propranolol strictly as a beta-adrenergic receptor antagonist. Its ability to influence non-coding RNA expression and downstream inflammatory pathways underscores a multifaceted pharmacological profile, suggesting that repurposing such drugs could exploit these novel mechanisms in other vascular pathologies.
Looking forward, the research community will be keen to explore pharmacological agents that can modulate the NEAT1/miR-194-5p/TRAF6 axis more selectively or potentiate propranolol’s effects, thereby enhancing therapeutic precision while minimizing off-target consequences. The development of RNA-based therapeutics, such as antisense oligonucleotides or miRNA mimics, might offer bespoke interventions for patients with refractory or complicated hemangiomas.
Importantly, this work exemplifies the convergence of molecular genetics, RNA biology, and clinical pharmacology, highlighting how cutting-edge research can translate into tangible improvements in patient care. Infants afflicted with disfiguring or functionally impairing hemangiomas might soon benefit from personalized approaches that harness the discovered signaling pathways to optimize healing.
The study also raises intriguing questions about the role of other long non-coding RNAs and microRNAs in endothelial cell behavior and vascular disease. The complexity of RNA-mediated regulation in angiogenesis demands further expansive research to chart the interconnected networks driving vascular development and pathology.
In summary, Wang, Hu, An, and colleagues have illuminated a previously uncharacterized molecular circuitry by which propranolol attenuates angiogenesis in infantile hemangiomas through modulating the NEAT1/miR-194-5p/TRAF6/NF-κB pathway. This breakthrough enhances our understanding of IH pathophysiology and heralds a new era of RNA-centric therapeutic strategies. It tantalizes the scientific and medical community with the promise of revolutionizing management approaches and improving outcomes for countless young patients worldwide.
Subject of Research: Infantile Hemangiomas and the molecular mechanisms of angiogenesis inhibition by propranolol.
Article Title: Inhibition of angiogenesis by propranolol in infantile hemangiomas via lncRNA NEAT1-mediated miR-194-5p/TRAF6/NF-κB pathway.
Article References:
Wang, H., Hu, Z., An, W. et al. Inhibition of angiogenesis by propranolol in infantile hemangiomas via lncRNA NEAT1-mediated miR-194-5p/TRAF6/NF-κB pathway. Pediatr Res (2026). https://doi.org/10.1038/s41390-026-04932-6
Image Credits: AI Generated
DOI: 29 April 2026
Tags: anti-angiogenic therapies for infantile hemangiomasbeta-blockers in pediatric vascular anomaliesendothelial cell proliferation regulationmicroRNA-194-5p role in vascular tumorsmolecular basis of propranolol efficacyNEAT1 long non-coding RNA in angiogenesisNF-κB pathway in hemangioma growthnon-coding RNA interactions in IHpropranolol mechanism in infantile hemangiomastargeted treatment strategies forTRAF6 signaling in endothelial cells
